AbbVie Header AbbVie Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Lion TCR","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lion TCR Receives FDA Fast Track Designation for its HBV-specific TCR T Cell Therapy for Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SINGAPORE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Lion TCR","sponsor":"MaxCyte","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"SINGAPORE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform"}]

    Find Clinical Drug Pipeline Developments & Deals by Lion TCR

    Menu

    Lion TCR

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Lion TCR

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Singapore
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline

              Details:

              Under the terms of the agreement, Lion TCR obtains worldwide non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform for the development of new TCR-T cell therapies for patients with solid tumors.

              Lead Product(s): TCR-T Cell Therapy

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

              Recipient: MaxCyte

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement January 03, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Lion TCR

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Singapore
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Lion TCR Receives FDA Fast Track Designation for its HBV-specific TCR T Cell Therapy for Hepatocellular Carcinoma

              Details:

              This designation was granted based on the efficacy of LioCyx-M004, an autologous T-cells transfected with mRNA encoding HBsAg, as demonstrated by an improvement in the overall survival in patients with HBsAg-positive HCC relapsed or refractory to prior systemic treatment.

              Lead Product(s): LioCyx-M004

              Therapeutic Area: Oncology Product Name: LioCyx-M004

              Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 23, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Naprod is a top player in Oncology & Anesthesia FDF through excellent innovation, discovery of new processes & high-quality production.
              Skyepharma, an Expert and Innovative CDMO Partner for tailor-made solutions in complex oral solids and bioproduction.
              Post Enquiry
              POST ENQUIRY